Mydgf Enhances Cardiac Angiogenesis by Upregulating FGF1

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Regenerative Medicine

Background:

• Endothelial cell proliferation is vital for neovascularization and cardiac repair post-myocardial infarction (MI).
• Myeloid-derived growth factor (Mydgf) is implicated in cardiac repair, but its role in angiogenesis is not well understood.

Purpose of the Study:

• To elucidate the mechanism by which Mydgf regulates cardiac angiogenesis.
• To investigate the therapeutic potential of the Mydgf-FGF1 axis in ischemic heart disease.

Main Methods:

• Utilized myeloid-derived growth factor knockout (Mydgf-KO) mouse models to assess cardiac angiogenesis and function post-MI.
• Employed liquid chromatography mass spectrometry (LC-MS) to identify downstream effectors of Mydgf in the cardiac extracellular matrix.
• Assessed endothelial cell proliferation and tube formation in vitro using recombinant FGF1 protein.

Main Results:

• Mydgf-KO mice exhibited reduced endothelial cell proliferation, impaired neovascularization, and worsened cardiac dysfunction after MI.
• Recombinant MYDGF therapy successfully reversed these deficits in Mydgf-KO mice.
• FGF1 was identified as a critical downstream effector of Mydgf in angiogenesis, with recombinant FGF1 promoting endothelial cell proliferation and tube formation.

Conclusions:

• The Mydgf-FGF1 axis is a key regulator of cardiac angiogenesis.
• This pathway holds significant therapeutic promise for promoting vascular repair in conditions like ischemic heart disease.